DE69923998T2 - Verwendung eines neurologischen wirkstoffes zur herstellung eines medikamentes zur behandlung von erkrankungen des zentralen nervensystems - Google Patents

Verwendung eines neurologischen wirkstoffes zur herstellung eines medikamentes zur behandlung von erkrankungen des zentralen nervensystems Download PDF

Info

Publication number
DE69923998T2
DE69923998T2 DE69923998T DE69923998T DE69923998T2 DE 69923998 T2 DE69923998 T2 DE 69923998T2 DE 69923998 T DE69923998 T DE 69923998T DE 69923998 T DE69923998 T DE 69923998T DE 69923998 T2 DE69923998 T2 DE 69923998T2
Authority
DE
Germany
Prior art keywords
agent
nerve
brain
fgf
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69923998T
Other languages
German (de)
English (en)
Other versions
DE69923998D1 (de
Inventor
H. William FREY
Gary Robert THORNE
Xueqing Chen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp filed Critical Chiron Corp
Application granted granted Critical
Publication of DE69923998D1 publication Critical patent/DE69923998D1/de
Publication of DE69923998T2 publication Critical patent/DE69923998T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Nutrition Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • AIDS & HIV (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE69923998T 1998-12-09 1999-12-09 Verwendung eines neurologischen wirkstoffes zur herstellung eines medikamentes zur behandlung von erkrankungen des zentralen nervensystems Expired - Fee Related DE69923998T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20853998A 1998-12-09 1998-12-09
US208539 1998-12-09
PCT/US1999/029335 WO2000033814A2 (en) 1998-12-09 1999-12-09 Method for administering agents to the central nervous system

Publications (2)

Publication Number Publication Date
DE69923998D1 DE69923998D1 (de) 2005-04-07
DE69923998T2 true DE69923998T2 (de) 2006-04-27

Family

ID=22774961

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69923998T Expired - Fee Related DE69923998T2 (de) 1998-12-09 1999-12-09 Verwendung eines neurologischen wirkstoffes zur herstellung eines medikamentes zur behandlung von erkrankungen des zentralen nervensystems

Country Status (6)

Country Link
EP (1) EP1135105B1 (cg-RX-API-DMAC10.html)
JP (1) JP2002531490A (cg-RX-API-DMAC10.html)
AT (1) ATE289800T1 (cg-RX-API-DMAC10.html)
AU (1) AU2173400A (cg-RX-API-DMAC10.html)
DE (1) DE69923998T2 (cg-RX-API-DMAC10.html)
WO (1) WO2000033814A2 (cg-RX-API-DMAC10.html)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1305294B1 (it) 1999-01-29 2001-05-04 Alessandro Lambiase Uso del nerve growth factor nella terapia di patologie a carico deitessuti intraoculari.
EP1602378A1 (en) * 1999-12-09 2005-12-07 Chiron Corporation Method for administering a cytokine to the central nervous system and the lymphatic system
WO2001041782A2 (en) * 1999-12-09 2001-06-14 Chiron Corporation Method for administering a cytokine to the central nervous system and the lymphatic system
CA2597525A1 (en) * 2005-02-17 2006-08-24 Senju Pharmaceutical Co., Ltd. Solid ophthalmic drug for external use
US20090136505A1 (en) 2005-02-23 2009-05-28 Johanna Bentz Intranasal Administration of Active Agents to the Central Nervous System
ITRM20050447A1 (it) * 2005-08-19 2007-02-20 Anabasis S R L Uso del nerve growth factor in collirio nella terapia di patologie del sistema nervoso centrale, quali la malattia di alzheimer e il morbo di parkinson.
JP5276982B2 (ja) 2005-08-26 2013-08-28 ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ オキシトシンの投与による頭痛の処置のための方法
WO2007127163A2 (en) 2006-04-24 2007-11-08 Geron Corporation Cns-tumor treatment method and composition
KR101760139B1 (ko) * 2007-06-29 2017-07-31 클라렌슈 피티와이 리미티드 안투여를 통한 신경 또는 신경정신 장애의 치료 또는 예방용 약학 조성물
WO2011072091A1 (en) 2009-12-09 2011-06-16 Quark Pharmaceuticals, Inc. Methods and compositions for treating diseases, disorders or injury of the cns
US8609088B2 (en) 2011-05-10 2013-12-17 Regents Of The University Of Minnesota Intranasal delivery of therapeutic enzymes to the central nervous system for the treatment of lysosomal storage diseases
US8987199B2 (en) 2011-06-15 2015-03-24 Nerve Access, Inc. Pharmaceutical compositions for intranasal administration for the treatment of neurodegenerative disorders
JP2016523835A (ja) 2013-05-15 2016-08-12 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ 中枢神経系へのアデノ随伴ウイルスを介した遺伝子導入
RS59490B1 (sr) 2014-11-21 2019-12-31 Biohaven Therapeutics Ltd Sublingvalna formulacija riluzola
WO2016085787A1 (en) * 2014-11-25 2016-06-02 Corning Incorporated Cell culture media extending materials and methods
PL3242676T3 (pl) 2015-01-07 2024-07-15 Tonix Pharma Limited Preparaty oksytocyny zawierające magnez i sposoby ich stosowania
US11207461B2 (en) 2015-07-30 2021-12-28 Anoop U. R Drug delivery system and method for controlled and continuous delivery of drugs into the brain by bypassing the blood brain barrier
WO2017017543A1 (en) * 2015-07-30 2017-02-02 U R Anoop Drug delivery system and method for controlled and continuous delivery of drugs into the brain by bypassing the blood brain barrier
HRP20250215T1 (hr) 2016-04-12 2025-06-20 Tonix Pharma Limited Formulacije oksitocina koje sadrže magnezij i postupci upotrebe
US11253612B2 (en) 2016-04-15 2022-02-22 The Trustees Of The University Of Pennsylvania Gene therapy for treating mucopolysaccharidosis type II
EP3509585B1 (en) * 2016-09-07 2023-11-01 Glia, LLC Treatment of symptoms related to neurodegenerative disorders through pharmacological dermal activation of cranial nerves
EP3684938A1 (en) 2017-09-22 2020-07-29 The Trustees of the University of Pennsylvania Gene therapy for treating mucopolysaccharidosis type ii

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0200757B1 (en) * 1984-10-19 1992-03-11 Chiron Corporation Promotion of wound healing with human epidermal growth factor prepared from recombinant dna
US5652214A (en) * 1989-06-05 1997-07-29 Cephalon, Inc. Treating disorders by application of insulin-like growth factors and analogs
CA2167104A1 (en) * 1995-01-17 1996-07-18 Joerg G.D. Birkmayer Nadh and nadph therapeutic agents for nasal, sublingual, rectal and dermal administration
JP3191038B2 (ja) * 1996-06-26 2001-07-23 輝夫 西田 眼科用医薬組成物
US5840736A (en) * 1996-11-13 1998-11-24 Vertex Pharmaceuticals Incorporated Methods and compositions for stimulating neurite growth
IT1289608B1 (it) * 1997-02-05 1998-10-15 Angelini Ricerche Spa Composizione per uso terapeutico o diagnostico somministrabile per via intranasale,sublinguale o vaginale

Also Published As

Publication number Publication date
WO2000033814A2 (en) 2000-06-15
AU2173400A (en) 2000-06-26
ATE289800T1 (de) 2005-03-15
JP2002531490A (ja) 2002-09-24
EP1135105B1 (en) 2005-03-02
WO2000033814A3 (en) 2000-11-30
DE69923998D1 (de) 2005-04-07
EP1135105A2 (en) 2001-09-26

Similar Documents

Publication Publication Date Title
DE69928563T2 (de) Abgeben von neurotropischen Wirkstoffen an das Zentralnervensystem
US7273618B2 (en) Method for administering agents to the central nervous system
EP1135105B1 (en) Use of a neurologic agent for the manufacture of a medicament for the treatment of a central nervous system disorder
US5624898A (en) Method for administering neurologic agents to the brain
DE60021760T2 (de) Verfahren zur verabreichung von wirkstoffen in das zentrale nervensystem oder lymphsystem
DE68911068T2 (de) EGF zur Vorbeugung von Gewebeschädigung nach Ischemie.
DE69432638T2 (de) Anwendung von HGF zur Herstellung eines Medikaments gegen Zentralnervensystemstörungen
EP0789584B1 (de) Applikation von sod in liposomen
US6407061B1 (en) Method for administering insulin-like growth factor to the brain
JP2002531490A5 (cg-RX-API-DMAC10.html)
DE69807710T2 (de) Verwendung von Latenz Assoziierten Peptiden in der Herstellung eines Medikaments zur Verbesserung der Wundheilung.
EP2289539A1 (de) Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
Baffour et al. Synergistic effect of basic fibroblast growth factor and methylprednisolone on neurological function after experimental spinal cord injury
US20210244794A1 (en) Stem Cell Stimulating Compositions for Treatment of Melasma
JPH09509140A (ja) 神経学的障害の治療方法
JP4102437B2 (ja) アクチビンおよびインヒビン刺激因子を含有する医薬組成物
MX2007014856A (es) Composicion de factor de crecimiento epidermico, un proceso para el mismo y su aplicacion.
EP2240198B1 (de) Zusammensetzung zur aufnahme über muköses gewebe
WO1997003689A1 (en) Method of treating epilepsy with brain derived neurotrophic factor
JP2011506413A (ja) 瘢痕化阻害の方法
DE202024100977U1 (de) Liposomale Formulierung mit kontrollierter Freisetzung von der Nase zum Gehirn bei neurologischen Erkrankungen
ES2371930T3 (es) Método para el tratamiento de una herida del sistema nervioso central por medio de administración reducida de progesterona.
JP2011506411A (ja) 瘢痕化阻害の方法
DE10317369A1 (de) proNGF als pharmazeutisch wirksames Mittel zur Behandlung demyelinisierender Erkrankungen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: NOVARTIS VACCINES AND DIAGNOSTICS,INC.(N.D.GES, US

8339 Ceased/non-payment of the annual fee